Files and links (1)
Published, Version of Record (VoR)CC BY-NC-ND V4.0, Open
Journal article
Tofacitinib-Associated Cerebral Venous Sinus Thrombosis
ACG case reports journal, v 8(7), pe00632
20 Jul 2021
PMID: 34307712
Featured in Collection : UN Sustainable Development Goals @ Drexel
Abstract
Tofacitinib is a Janus kinase inhibitor indicated to treat adult patients with moderately to severely active ulcerative colitis (UC). Although thrombosis is a known adverse event of tofacitinib, there are no reports specific to cerebral venous sinus thrombosis (CVST). We present a report of a patient presenting with a CVST several months after starting tofacitinib. Initially, this 60-year-old man with poorly controlled UC who previously had a nonthrombotic hemorrhage was found to have venous sinus thromboses of the right transverse and sigmoid sinuses. Hematological workup did not reveal any underlying hypercoagulable conditions, aside from UC. This is the first report of a patient with CVST likely resulting from the Janus kinase inhibitor tofacitinib. This case report should prompt compilation of all thrombotic events in patients receiving tofacitinib.
Metrics
8 Record Views
Details
- Title
- Tofacitinib-Associated Cerebral Venous Sinus Thrombosis
- Creators
- Zakaria Hakma - Neurosciences InstituteNatalie Gofman - Neurosciences InstituteDanielle Brown - Neurosciences InstituteEthan Fitzgerald - Drexel University
- Publication Details
- ACG case reports journal, v 8(7), pe00632
- Publisher
- Wolters Kluwer
- Resource Type
- Journal article
- Language
- English
- Academic Unit
- Neurology
- Web of Science ID
- WOS:000711688600014
- Other Identifier
- 991019167128504721
UN Sustainable Development Goals (SDGs)
This publication has contributed to the advancement of the following goals:
InCites Highlights
Data related to this publication, from InCites Benchmarking & Analytics tool:
- Web of Science research areas
- Gastroenterology & Hepatology